Safety and efficacy of ABT 378/r in the German expanded access program (EAP)

被引：0
|
作者：
Voigt, E
Wasmuth, JC
Braitinger, D
Kupfer, B
Kaiser, R
Rockstroh, JK
机构：
[1] Univ Bonn, Dept Internal Med, D-5300 Bonn, Germany
[2] Univ Bonn, Dept Virol, D-5300 Bonn, Germany
[3] Univ Cologne, Dept Virol, D-5000 Cologne, Germany
来源：
AIDS | 2000年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P45
引用
收藏
页码：S29 / S30
页数：2
相关论文
共 50 条
  • [1] Results of the Afatinib Expanded Access Program (EAP): Efficacy and Safety
    Kim, E. S.
    Halmos, B.
    Kohut, I. F.
    Patel, T.
    Rostorfer, R. D.
    Spira, A. I.
    Cseh, A.
    McKay, J.
    Wallenstein, G.
    Mileham, K. F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S40 - S40
  • [2] ABT-378/ritonavir (ABT-378/r) and efavirenz: one year safety/efficacy evaluation in multiple PI experienced patients
    Rockstroh, J
    Brun, S
    Sylte, J
    Xu, Y
    Clumeck, N
    Lazzarini, A
    Girard, PM
    Becker, S
    Telenti, A
    Bergmann, F
    Danner, S
    Ho, D
    Tubiana, R
    Carosi, G
    Bertz, R
    Hsu, A
    Kempf, DJ
    Sun, E
    AIDS, 2000, 14 : S29 - S29
  • [3] Efficacy and Safety Results of the Afatinib Expanded Access Program
    Edward S. Kim
    Balazs Halmos
    Ingrid F. Kohut
    Taral Patel
    Regan D. Rostorfer
    Alexander I. Spira
    Agnieszka Cseh
    John McKay
    Gudrun Wallenstein
    Kathryn F. Mileham
    Oncology and Therapy, 2017, 5 (1) : 103 - 110
  • [4] Cabazitaxel in patients with advanced CRPC after docetaxel failure: Results of expanded program access (EAP) in Spain: Safety and efficacy
    De Velasco, Guillermo
    Anton Aparicio, Luis
    Esteban, Emilio
    Perez, Quionia
    Sanchez-Hernandez, Alfredo
    Perez-Valderrama, Begona
    Batista, Norberto
    Sepulveda, Juan
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Expanded access program (EAP) to investigational drugs.
    Talarico, L
    Pazdur, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 519S - 519S
  • [6] Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
    Vitale, Maria Giuseppa
    Scagliarini, Sarah
    Galli, Luca
    Pignata, Sandro
    Lo Re, Giovanni
    Berruti, Alfredo
    Defferrari, Carlotta
    Spada, Massimiliano
    Masini, Cristina
    Santini, Daniele
    Ciuffreda, Libero
    Ruggeri, Enzo Maria
    Bengala, Carmelo
    Livi, Lorenzo
    Fagnani, Daniele
    Bonetti, Andrea
    Giustini, Lucio
    Hamzaj, Alketa
    Procopio, Giuseppe
    Caserta, Claudia
    Sabbatini, Roberto
    PLOS ONE, 2018, 13 (07):
  • [7] CABAZITAXEL IN PATIENTS WITH ADVANCED CRPC AFTER DOCETAXEL-FAILURE. RESULTS OF EXPANDED PROGRAM ACCESS (EAP) IN SPAIN: SAFETY AND EFFICACY
    Castellano, D. E.
    Anton Aparicio, L. M.
    Esteban, E.
    Velasco, G.
    Perez, Q.
    Sanchez, A.
    Perez-Valderrama, B.
    Batista, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 314 - 314
  • [8] Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)
    Procopio, G.
    Prisciandaro, M.
    Iacovelli, R.
    Mancini, M.
    Fornarini, G.
    Facchini, G.
    Carteni, G.
    Napolitano, M.
    Sternberg, C. N.
    Caserta, C.
    Bregni, M.
    Massari, F.
    Buti, S.
    Biasco, E.
    De Giorgi, U.
    Zustovich, F.
    Ratta, R.
    Ortega, C.
    Tortora, G.
    Verzoni, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)
    Michele, P.
    Ratta, R.
    Iacovelli, R.
    Mancini, M.
    Fornarini, G.
    Facchini, G.
    Carteni, G.
    Napolitano, M.
    Del Bene, G.
    Santini, D.
    Soraru, M. Mariella
    Vitale, M. G.
    Ricotta, R.
    Tucci, M.
    Fedeli, S. Luzi
    Boe, M. G.
    Mecozzi, A.
    Ortega, C.
    Stemberg, C. N.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).
    De Giorgi, Ugo
    Scagliarini, Sarah
    Basso, Umberto
    Galli, Luca
    Mosillo, Claudia
    Caserta, Claudia
    Rossetti, Sabrina
    Guida, Annalisa
    Bearz, Alessandra
    Buti, Sebastiano
    Lo Re, Giovanni
    Valcamonico, Francesca
    Hamzaj, Alketa
    Cognetti, Francesco
    Rastelli, Francesca
    Fornarini, Giuseppe
    Porta, Camillo
    Del Bene, Gabriella
    Turci, Daniele
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345